Project Grant HT94252510469
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award of $518,700.00 was made by the Defense Health Agency on July 1, 2024 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The award is part of the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public. The funding will support Bidmc's project titled "EXPLOITING DISRUPTION IN TRANSCRIPTIONAL...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
The Department of the Army Medical Command awarded Beth Israel Deaconess Medical Center, Inc. (BIDMC) a $1.3 million Project Grant over four years from July 2021 to June 2025 under the Military Medical Research and Development program (CFDA 12.420). The grant will fund BIDMC's research project "BH3 MIMETIC DRUGS FOR PROSTATE CANCER THERAPY." Through this funding, BIDMC researchers will investigate medical solutions for prostate cancer by developing BH3 mimetic drugs to transform...
This Cooperative Agreement award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program provides funding of $1,028,005.00 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) in Boston, MA. The award supports BIDMC's role as a clinical trials site for the Kidney Cancer Research Consortium, advancing research and interventions in kidney cancer. The award provides funding for the initial performance period from September 15, 2024 through...
This $345,800 Project Grant was awarded on May 1, 2024 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The grant supports research on the "Role of Stress Granules in the Pathogenesis and Therapy of Pulmonary Hypertension", with a performance period from May 1, 2024 to April 30, 2026. The Military Medical Research and Development program funds a...
The Defense Health Agency awarded a $1,412,826 Project Grant on September 1, 2023 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research through the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "Identification of Risk and Early Detection Biomarkers for Liver Cancer," will support a 3-year study led by Dr. Towia Libermann at Bidmc, with a sub-award to Vanderbilt University Medical Center (VUMC) to assist with case...
The Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) received a $1,735,624 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from July 1, 2021 to June 30, 2025 to develop a strain-programmable bioadhesive patch to accelerate healing of diabetic ulcers. The Military Medical Research and Development program aims to transform military and public health through innovative...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $772,626 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). The research, which commenced on August 1, 2025 and is scheduled for completion by July 31, 2028, aims to transform healthcare for military service...
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...